Every Form 4 that Travere Therapeutics, Inc. (TVTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TVTX filings page.
Travere Therapeutics, Inc. (TVTX) reported that its Chief Research Officer, William E. Rote, exercised employee stock options for a total of 191,500 shares of common stock on September 15-16, 2026, at exercise prices including $15.46, $17.96, $25.25 and $26.88 per share. Over the same two days he sold an aggregate of 209,048 shares of common stock in open-market transactions at weighted average prices generally in the low-to-mid $60s per share. The sales were made pursuant to a written trading plan adopted on June 16, 2026, that meets the requirements of Rule 10b5-1(c), and the stock options exercised were reported as fully vested and exercisable.
Travere Therapeutics, Inc. (TVTX) reported that EVP and Chief Commercial Officer Peter Heerma exercised employee stock options and sold shares of common stock over September 15–17, 2026. He exercised 258,189 options at strike prices between $8.93 and $26.88 per share and sold 283,189 shares of common stock in market transactions pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) executive Jula Inrig, EVP, Head of R&D & CMO, reported an option exercise and related share sales. On September 15, 2026, she exercised 32,395 employee stock options at $8.93 per share, receiving the same number of common shares, and subsequently sold 44,674 shares of common stock in a series of brokerage or private transactions at prices around the low-to-mid $60s per share. Following the option exercise, 43,605 options under that grant remain directly held and are scheduled to expire on January 31, 2034. The reported sales were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) reported that its Chief Legal Officer and General Counsel, Elizabeth E. Reed, exercised 37,500 stock options for common shares at an exercise price of $15.46 per share on September 15, 2026, then sold 37,500 common shares in multiple open-market transactions the same day. The option was fully vested and exercisable, and the sales were made pursuant to a written trading plan adopted on June 16, 2026 that meets the requirements of Rule 10b5-1(c).
Travere Therapeutics, Inc. (TVTX) reported that Chief Executive Officer and director Eric M. Dube exercised employee stock options for a total of 400,000 shares of common stock at an exercise price of $23.34 per share on September 15–17, 2026, and sold 400,000 shares of common stock in open-market transactions on the same dates. The sales were made under a written trading plan adopted on June 16, 2026, that meets Rule 10b5-1(c) requirements, and the options exercised were fully vested and exercisable.
Travere Therapeutics, Inc. (TVTX) reports that its chief financial officer, Christopher R. Cline, exercised employee stock options for 20,000 shares of common stock at an exercise price of $17.44 per share on September 15, 2026, and the corresponding option position was reduced to zero. On the same date, he sold an aggregate of 50,508 shares of common stock in multiple open-market transactions at weighted average prices between approximately $62.00 and $65.31 per share. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) reported that Sandra Calvin, its SVP, Chief Accounting Officer, exercised employee stock options for a total of 5,375 shares of common stock on September 15, 2026 at strike prices of $27.50, $22.40, and $20.46 per share, and on the same date sold 5,375 shares of common stock in multiple transactions at weighted average prices between about $62.14 and $63.66. The sales were made pursuant to a Rule 10b5-1(c) trading plan adopted on June 16, 2026.
Travere Therapeutics, Inc. (TVTX) director Jeffrey A. Meckler reported option exercises and related share sales on September 10, 2026. He exercised stock options for 10,000 shares at $17.44 and 10,000 shares at $26.52, receiving a total of 20,000 shares of common stock.
On the same date, he sold 20,000 shares of common stock in market transactions, split into four tranches of 1,700; 1,200; 14,000; and 3,100 shares at weighted average prices of $65.3917, $66.15, $67.4634, and $68.088, respectively. These sales were made under a Rule 10b5-1(c) trading plan adopted on June 11, 2026, and involved shares underlying fully vested options expiring in 2027 and 2028.
Travere Therapeutics, Inc. (TVTX) reported that its Chief Financial Officer, Christopher R. Cline, sold 642 shares of common stock on September 2, 2026 at $66.37 per share. According to the company’s disclosure, this sale was a mandatory “sell to cover” transaction to satisfy tax withholding on vested restricted stock units and was not a discretionary trade by the officer, and no Rule 10b5-1 trading plan is reported.
Travere Therapeutics, Inc. (TVTX) director Gary A. Lyons reported an exercise-and-sell sequence over August 17–18, 2026. He exercised stock options for 10,000 shares of common stock at an exercise price of $17.44 per share (options fully vested and expiring May 17, 2027), acquiring 10,000 shares. He then sold 10,000 shares of common stock in multiple tranches at weighted-average prices ranging from about $62.53 to $64.16 per share. All sales were made pursuant to a written trading plan adopted on May 18, 2026 under Rule 10b5-1(c).
Travere Therapeutics, Inc. chief medical officer Jula Inrig reported a bona fide gift of 468 shares of common stock to a donor-advised fund. The gift was authorized on June 16, 2026, and transferred on June 22, 2026, at a reported price of $0.00 per share. Following this charitable transfer, Inrig directly holds 112,770 shares of Travere Therapeutics common stock, indicating this was a relatively small, non-market transaction within her overall position.
Travere Therapeutics director Timothy Coughlin reported an option exercise combined with a share sale. He exercised stock options for 10,000 shares of common stock at an exercise price of $26.52 per share and sold 10,000 shares in an open-market transaction at a weighted average price of $50.0747 per share.
The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025, indicating it was scheduled in advance. Following these transactions, Coughlin directly holds 56,250 shares of Travere Therapeutics common stock.
Travere Therapeutics director Roy D. Baynes reported an options exercise and share sale. On the same date, he exercised stock options to acquire 4,500 shares of common stock at $21.38 per share and sold 4,500 shares in an open-market transaction at $50.00 per share.
The filing notes the sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025. After these transactions, Baynes directly holds 41,500 shares of Travere Therapeutics common stock.
Travere Therapeutics, Inc. director Ruth Williams Brinkley received an automatic equity grant under the company’s 2018 Equity Incentive Plan pursuant to its non-employee director compensation program. The award includes 4,000 shares of common stock and stock options for 12,000 shares at an exercise price of $42.26 per share.
The equity award vests over a one-year period. The stock options become exercisable beginning on May 19, 2027 and expire on May 19, 2036. Following the stock grant, Brinkley directly holds 29,750 shares of Travere Therapeutics common stock.
Travere Therapeutics director Ron Squarer received new equity compensation. He was granted 4,000 shares of common stock as an automatic equity grant under the company’s 2018 Equity Incentive Plan, pursuant to the non-employee director compensation program. Following this award, he directly holds 39,375 common shares.
Squarer was also granted stock options covering 12,000 shares of common stock with a conversion price of $42.26 per share. The equity award vests over a one-year period, and the options are exercisable from May 2027 and expire in May 2036, reflecting routine board-level compensation rather than open-market trading.
Travere Therapeutics director Sandra Poole received equity compensation in the form of shares and options. On May 19, 2026, she was granted 4,000 shares of common stock at no cost under Travere’s 2018 Equity Incentive Plan as part of the non-employee director compensation program. Following this grant, she directly holds 34,000 common shares. On the same date, she also received a stock option for 12,000 shares of common stock with an exercise price of $42.26 per share, expiring in 2036. The award vests over one year, indicating a time-based service requirement rather than an open-market purchase.
Travere Therapeutics director John A. Orwin reported equity awards. He received 4,000 shares of common stock as an automatic equity grant under Travere’s 2018 Equity Incentive Plan, pursuant to the non-employee director compensation program. Following this award, he directly holds 39,375 common shares.
Orwin was also granted stock options for 12,000 shares of common stock at an exercise price of $42.26 per share. These options begin exercisability on May 19, 2027, expire on May 19, 2036, and the equity award vests over one year.
Meckler Jeffrey A reported acquisition or exercise transactions in this Form 4 filing.
Travere Therapeutics director Jeffrey A. Meckler received new equity compensation. He was granted 4,000 shares of common stock and 12,000 stock options as an automatic equity grant under Travere’s 2018 Equity Incentive Plan and non-employee director compensation program.
The options give him the right to buy 12,000 shares of common stock at $42.26 per share and expire on May 19, 2036. The equity award vests over a one year period. After the grant, he directly owns 91,500 common shares and holds 12,000 stock options.
Travere Therapeutics director Gary A. Lyons received new equity awards as part of his board compensation. He was granted 4,000 shares of common stock at no cost under the company’s 2018 Equity Incentive Plan for non-employee directors, increasing his direct holdings to 61,500 shares.
Lyons was also granted stock options for 12,000 shares of common stock at an exercise price of $42.26 per share, expiring in 2036. The equity award vests over a one year period, making this a routine, compensation-related acquisition rather than an open-market purchase.
Travere Therapeutics, Inc. director Timothy Coughlin reported receiving equity compensation consisting of common shares and stock options. On May 19, 2026, he was granted 4,000 shares of Common Stock, increasing his direct holdings to 56,250 shares. He was also granted stock options for 12,000 shares of Common Stock at an exercise price of $42.26 per share, exercisable starting May 19, 2027 and expiring on May 19, 2036. The filing notes these are automatic equity grants under Travere’s 2018 Equity Incentive Plan for non-employee director compensation, with the equity award vesting over one year.
Travere Therapeutics director Suzanne Louise Bruhn received new equity awards as part of the company’s non-employee director compensation program. She was granted 4,000 shares of common stock, bringing her direct holdings to 32,750 shares after the transaction. She also received stock options covering 12,000 shares of common stock at an exercise price of $42.26 per share. The filing states these awards were automatic grants under Travere’s 2018 Equity Incentive Plan and that the equity award vests over a one-year period.
Baynes Roy D. reported acquisition or exercise transactions in this Form 4 filing.
Travere Therapeutics director Roy D. Baynes received new equity compensation awards. He was granted 4,000 shares of common stock at no cost and a stock option covering 12,000 shares with a strike price of $42.26 per share.
The awards were made as an automatic equity grant under Travere’s 2018 Equity Incentive Plan pursuant to the non-employee director compensation program. The equity award vests over one year, and following the stock grant Baynes directly holds 41,500 shares of common stock.
Travere Therapeutics, Inc. director Timothy Coughlin reported an open-market sale of 3,250 shares of common stock at $43.49 per share. The transaction took place on May 15, 2026 and was executed under a pre-arranged Rule 10b5-1 trading plan. After the sale, he directly holds 52,250 shares.
Travere Therapeutics director Roy D. Baynes exercised stock options and sold the resulting shares in a pre-planned transaction. On May 5, he exercised options for 4,500 shares of common stock at $18.27 per share and sold 4,500 shares at $46.65 per share in an open-market sale. The sale was made under a written Rule 10b5-1(c) trading plan adopted on November 17, 2025 and involved fully vested, exercisable options. After these transactions, Baynes directly owns 37,500 shares of Travere Therapeutics common stock, with no remaining position from the exercised options.
Travere Therapeutics director Jeffrey A. Meckler exercised stock options for 8,000 shares of common stock at $16.33 per share, then sold 8,000 shares at $45.00 per share in an open‑market transaction. The sale was made under a pre‑arranged Rule 10b5‑1(c) trading plan. Following these transactions, Meckler directly owns 87,500 shares of Travere Therapeutics common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported a mix of equity award activity and a small share sale. On May 4, 2026, 4,250 performance-based restricted stock units converted into common stock after a cumulative FILSPARI net revenue performance criterion was met, and he received a new grant of 8,500 performance-based units. The filing notes that an additional 25% of these units is scheduled to vest on January 31, 2027, contingent on continued service. On May 6, 2026, he sold 2,763 shares of common stock at $43.95 per share under a pre-arranged Rule 10b5-1 trading plan that also covered tax obligations from the vesting. Following the transactions, he directly holds 115,474 common shares.
Travere Therapeutics, Inc. Chief Legal Officer and General Counsel Elizabeth E. Reed reported a mix of option exercises, PSU activity and share sales. On May 4, 2026 she exercised employee stock options and performance-based restricted stock units covering a total of 24,250 shares of common stock, including 20,000 options at a $17.96 exercise price.
That same day, she sold 20,000 shares at $45.00 per share, and on May 5 and 6, 2026 she sold additional blocks of 2,174 shares at $46.65 and 2,076 shares at $43.95. Footnotes state that certain sales were made under a Rule 10b5‑1 trading plan and that some shares were sold to cover tax withholding obligations related to vested performance-based RSUs, rather than as discretionary trades. After these transactions, she directly held 105,211 shares of Travere common stock and performance-based restricted stock units covering 8,500 shares at target.
Travere Therapeutics Chief Medical Officer Jula Inrig reported a combination of equity award activity and stock sales. On May 4, 2026, she exercised 20,000 employee stock options with a $22.40 exercise price and sold 20,000 shares of common stock at $45.00 per share, alongside the vesting and conversion of 4,250 performance-based restricted stock units (PSUs) into common stock.
On May 5 and 6, 2026, she sold additional blocks of 2,174 and 311 shares at $46.65 and $43.95 per share. Footnotes state that certain sales, including tax “sell to cover” transactions, were conducted under a pre-arranged Rule 10b5-1 trading plan rather than as fully discretionary trades. Following these transactions, Inrig directly holds 113,238 shares of common stock, plus 34,500 stock options and 8,500 PSUs subject to future vesting conditions.
Travere Therapeutics’ chief commercial officer Peter Heerma reported a mix of equity award vesting and a required tax-related sale. On May 4, 2026, 4,250 performance-based restricted stock units (PSUs) vested, converting into 4,250 shares of common stock after Travere confirmed a FILSPARI cumulative net revenue performance milestone tied to results for the quarter ended March 31, 2026.
Those PSUs are part of an 8,500-unit grant awarded on January 31, 2024, with an additional 25% scheduled to vest on January 31, 2027, contingent on continued service. The filing notes that up to 50% additional shares could vest later if certain milestones are achieved on an accelerated timeline. On May 5, 2026, Heerma sold 2,174 shares at $46.65 per share to cover tax withholding obligations under a mandatory “sell to cover” arrangement chosen by the company, described as a non-discretionary sale. After these transactions, he directly holds 140,684 shares of Travere common stock.
Travere Therapeutics CEO Eric M. Dube exercised performance-based restricted stock units and sold shares in a planned, routine transaction. On May 6, 2026, he sold 22,500 shares of common stock at $43.95 per share in an open-market trade under a pre-arranged Rule 10b5-1(c) plan that also covered tax obligations from vesting.
Two days earlier, on May 4, 2026, he exercised 22,500 performance-based restricted stock units into common shares and received a new grant covering 45,000 PSUs. The filing states 50% of these PSUs vested after a cumulative FILSPARI net revenue performance target was confirmed, with an additional 25% scheduled to vest on January 31, 2027 if he remains in continuous service.
After these transactions, Dube directly holds 432,886 shares of Travere Therapeutics common stock, indicating he retains a substantial equity stake.
Travere Therapeutics’ CFO Christopher R. Cline reported a mix of equity awards, vesting and share sales. On May 4, 2026, he exercised performance-based restricted stock units (PSUs) covering 4,250 shares of common stock at a conversion price of $0.00 per share, following the vesting of 50% of PSUs originally granted on January 31, 2024. Those PSUs vested after the company confirmed that a performance criterion tied to cumulative FILSPARI net revenue for the quarter ended March 31, 2026 had been achieved. The same grant allows up to 50% additional shares to vest on an accelerated timeline and provides that a further 25% will vest on January 31, 2027, contingent on continued service.
Also on May 4, 2026, he received a new grant of 8,500 PSUs, each representing a contingent right to one share of common stock at target, subject to performance adjustments. On May 5 and May 6, 2026, he sold a total of 2,491 shares of common stock at prices of $46.65 and $43.95 per share. According to the footnotes, these sales were executed under a written Rule 10b5-1(c) trading plan adopted on May 28, 2025 and include shares sold to cover tax withholding obligations arising from PSU vesting. After these transactions, he directly owned 118,658 shares of Travere Therapeutics common stock.
Travere Therapeutics, Inc. director Roy D. Baynes carried out an exercise-and-sell transaction involving company stock. On May 1, 2026, he exercised stock options to acquire 9,750 shares of common stock at $6.82 per share, then sold 9,750 shares in an open-market transaction at $44.22 per share.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025, indicating it was scheduled in advance. Following these transactions, Baynes directly holds 37,500 shares of Travere common stock, and the exercised option is now fully vested and exercisable with no remaining derivative position from that specific grant.
Travere Therapeutics, Inc. Chief Research Officer William E. Rote reported an open-market sale of 9,100 shares of common stock at $39.09 per share. After this transaction, he directly holds 113,987 shares. The sale was executed under a pre-arranged Rule 10b5-1(c) trading plan and includes shares sold to cover tax obligations from vesting performance restricted stock units.
Travere Therapeutics director Gary A. Lyons exercised stock options and sold shares on the same day. He exercised options for 8,000 shares of Common Stock at an exercise price of $16.3300 per share, then sold 8,000 shares at $41.0700 per share.
The sale was carried out under a pre-arranged Rule 10b5-1(c) trading plan adopted on November 11, 2025, and involved shares underlying options expiring on May 18, 2026. Following these transactions, he directly holds 57,500 shares of Travere Therapeutics Common Stock.
Travere Therapeutics director Roy D. Baynes exercised stock options and sold shares in a planned transaction. He exercised options covering 32,750 shares of common stock at exercise prices between $15.43 and $21.38 per share, then sold 32,750 shares in open-market trades at $41.07 and $42.12 per share under a Rule 10b5-1 trading plan adopted on November 17, 2025. After these transactions, he directly owned 37,500 shares of Travere Therapeutics common stock.
Travere Therapeutics SVP and Chief Accounting Officer Sandra Calvin reported an option exercise and share sale. On April 14, 2026, she exercised employee stock options covering 15,250 shares of common stock at exercise prices of $22.40, $8.93, and $20.46 per share. She then sold 21,977 shares of common stock at $41.07 per share in an open-market transaction made under a pre-arranged Rule 10b5-1 trading plan adopted on June 10, 2025. After these transactions, she directly held 42,353 shares of Travere Therapeutics common stock.
Travere Therapeutics, Inc. chief commercial officer Peter Heerma reported a grant of 14,000 shares of common stock and a related share sale. The 14,000-share award on April 13, 2026 reflects settlement of performance restricted stock units tied to FDA approval of FILSPARI in FSGS. On April 14, 2026, he sold 7,215 shares at an average price of $41.9288 solely to cover tax withholding on the vested units under the company’s equity incentive plan. Following these transactions, he directly holds 138,608 shares of Travere common stock.
Travere Therapeutics Chief Research Officer William E. Rote reported receiving 14,000 shares of common stock as an equity award. The shares were acquired at no cost and are tied to performance restricted stock units granted on January 31, 2025.
According to the disclosure, these PSUs vested on April 13, 2026 after Travere confirmed that the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS. Following this vesting and share issuance, Rote directly holds 123,087 shares of Travere Therapeutics common stock, reflecting both this award and his existing stake.
Travere Therapeutics, Inc. director and CEO Eric M. Dube reported a PSU vesting and related share sales. On April 13, 2026, he acquired 64,000 shares of common stock at no cost through vested performance restricted stock units, triggered by FDA approval of FILSPARI (sparsentan) in FSGS.
On April 15, 2026, he sold 56,815 shares at a weighted average price of $41.01, 7,165 shares at a weighted average price of $41.75, and 20 shares at $42.66, all in open-market transactions under a Rule 10b5-1 trading plan that also covered tax obligations from the PSU vesting. Following these transactions, he directly holds 432,886 shares of Travere common stock, the same level as before the grant and sales.
Travere Therapeutics, Inc.’s Chief Legal Officer and General Counsel Elizabeth E. Reed exercised employee stock options and sold shares of common stock in a series of transactions. She exercised options to acquire 37,500 shares at exercise prices of $19.08, $17.96, and $15.46 per share and also received 14,000 shares as a grant or award.
Ms. Reed then sold a total of 51,500 shares of common stock in open-market and related transactions at weighted average prices around $41–$43 per share, leaving her with 105,211 shares owned directly after the transactions. Footnotes state that certain sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025 and that part of the sales were mandatory “sell to cover” trades to satisfy tax withholding obligations.
The 14,000-share award reflects performance restricted stock units granted on January 31, 2025 that vested on April 13, 2026 after the U.S. Food and Drug Administration approved FILSPARI (sparsentan) in FSGS.
Travere Therapeutics’ chief financial officer, Christopher R. Cline, reported a mix of equity compensation and share sales in Travere Therapeutics, Inc. common stock. He received 14,000 shares on April 13, 2026 as a grant tied to performance restricted stock units that vested after the U.S. Food and Drug Administration approved FILSPARI (sparsentan) for FSGS.
Between April 13 and 15, 2026, he sold a total of 8,327 shares in open-market transactions at prices ranging from about $28.85 to $42.61. Footnotes explain that part of these sales were mandated “sell to cover” transactions to satisfy tax withholding on vested restricted and performance stock units, and others were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. After these transactions, he directly holds 116,899 shares of Travere common stock.
Travere Therapeutics’ chief medical officer Jula Inrig reported a mix of equity award vesting and routine share sales. On April 13, 2026, 14,000 shares of common stock were acquired at no cost upon the vesting of performance restricted stock units tied to FDA approval of FILSPARI (sparsentan) in FSGS.
On April 14, 2026, Inrig sold 7,215 shares of common stock at an average price of $41.9288 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on May 28, 2025. On April 15, 2026, a further 1,018 shares were sold at $42.61 per share to cover tax withholding obligations related to the PSU settlement, as required by the company’s equity incentive plans. Following these transactions, Inrig held 111,473 shares of Travere Therapeutics common stock directly.
Travere Therapeutics director Roy D. Baynes exercised and sold shares in a planned transaction. On April 6, 2026, he exercised stock options for 10,000 shares of Common Stock at an exercise price of $26.52 per share and received 10,000 shares.
That same day, he completed an open-market sale of 10,000 Common Stock shares at $33.00 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 17, 2025. Following these transactions, Baynes directly holds 37,500 Common Stock shares.
Travere Therapeutics CEO Eric M. Dube exercised stock options covering 60,000 shares of common stock at $15.46 per share on April 1, 2026, then sold the same 60,000 shares in the open market.
The sales were split between 34,902 shares at $30.55 and 25,098 shares at $31.46, executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on June 16, 2025. After these transactions, Dube directly holds 432,886 shares of Travere common stock.
Travere Therapeutics Chief Legal Officer Elizabeth E. Reed exercised employee stock options and sold shares in a planned transaction. She exercised options for 10,000 shares of common stock at $15.46 per share and then sold 10,000 shares at $30.00 per share on the same day. After these transactions, she directly holds 105,211 shares of Travere Therapeutics common stock. The filing notes the sale was made under a written plan adopted on June 16, 2025 that meets Rule 10b5-1(c) requirements, and that the underlying stock option grant from January 31, 2020 is fully vested and exercisable.
Travere Therapeutics’ Chief Legal Officer Elizabeth E. Reed exercised employee stock options to acquire 10,000 shares of common stock at an exercise price of $19.08 per share, then sold 10,000 shares at a weighted average price of $28.0861 per share.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025, tied to a stock option grant expiring on January 4, 2027. Following these transactions, Reed holds 105,211 shares of Travere Therapeutics common stock directly.
Travere Therapeutics, Inc. CEO Eric M. Dube exercised stock options for 60,000 shares on February 20, 2026, converting an employee stock option into common stock at an exercise price of $15.4600 per share. He then sold 60,000 common shares in an open-market transaction at a weighted average price of $30.0961, under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, his directly held common stock position was 432,886 shares.
Travere Therapeutics, Inc. executive Elizabeth E. Reed, the Chief Legal Officer and General Counsel, reported option exercises and share sales in Travere stock. On February 17, 2026, she exercised an employee stock option for 10,000 shares, acquiring the same number of Travere common shares at a reported exercise price of $19.08 per share. The option, granted on January 4, 2017 and expiring on January 4, 2027, is fully vested and exercisable. On the same date, she sold 5,679 shares at a weighted average price of $27.504 and 4,321 shares at a weighted average price of $28.262, in each case under a prearranged Rule 10b5-1 trading plan adopted on June 16, 2025. Following these transactions, she directly owns 105,211 shares of Travere common stock.
Travere Therapeutics, Inc. Chief Medical Officer Jula Inrig reported planned sales of company stock. On February 4, 2026, Inrig sold 1,547 Travere common shares at a weighted average price of $32.11 and an additional 232 shares at a weighted average price of $32.85.
These transactions were made under a written trading plan adopted on May 28, 2025 that meets Rule 10b5-1(c) requirements and include shares sold to cover tax obligations from vesting restricted stock units. Following these sales, Inrig directly held 105,706 Travere common shares.
Travere Therapeutics, Inc. chief financial officer Christopher R. Cline reported two open‑market sales of company common stock on February 4, 2026. He sold 1,635 shares at a weighted average price of $32.14 and 110 shares at $32.90, and continued to hold 111,226 shares directly afterward.
According to the filing, these transactions were executed under a pre‑established Rule 10b5‑1 trading plan adopted on May 28, 2025, and include sales to cover tax obligations arising from the vesting of restricted stock units.